Zobrazeno 1 - 4
of 4
pro vyhledávání: '"David Groteluschen"'
Autor:
David Groteluschen, Sam J. Lubner, Jens C. Eickhoff, Rory Joseph Makielski, Anne M. Traynor, Noelle K. LoConte, Daniel Mulkerin
Publikováno v:
Cancer Chemotherapy and Pharmacology. 76:317-323
Fluoropyrimidines and oxaliplatin have demonstrated some efficacy against pancreatic adenocarcinoma, but survival remains brief. Sorafenib is an oral multikinase inhibitor which we sought to combine with a unique capecitabine and oxaliplatin regimen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ba0820cf687184629c83b6f203fcf68
https://doi.org/10.1007/s00280-015-2783-y
https://doi.org/10.1007/s00280-015-2783-y
Publikováno v:
Clinical Colorectal Cancer. 3:121-123
Capecitabine is an oral fluoropyrimidine used for cancer treatment. It is generally well tolerated. A patient who had previously received adjuvant 5-fluorouracil without neurotoxicity had a severe adverse reaction when later given capecitabine in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7dc1854d180c8386a88bb9f7b6c518a
https://doi.org/10.3816/ccc.2003.n.019
https://doi.org/10.3816/ccc.2003.n.019
Autor:
Kyle D. Holen, Kurt R. Oettel, Timothy Goggins, Hilary R. Hernan, Anne M. Traynor, Sam J. Lubner, Emily Robinson, William R. Schelman, Daniel Mulkerin, Dustin A. Deming, David Groteluschen, Noelle K. LoConte
Publikováno v:
Investigational new drugs. 31(4)
Chemotherapy has yielded minimal clinical benefit in pancreatic and biliary tract cancer. A high-dose, short course capecitabine schedule with oxaliplatin, has shown some efficacy with a lower incidence of palmar-plantar erythrodysesthesia. Achieving
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14c2ee1b6c5fc4ad1c446101ecf562d3
https://pubmed.ncbi.nlm.nih.gov/23263993
https://pubmed.ncbi.nlm.nih.gov/23263993
Autor:
Joan H. Schiller, Sarah M. Marcotte, Jill M. Kolesar, Kathleen Schell, David Groteluschen, Anne M. Traynor, Igor Espinoza-Delgado, Jens C. Eickhoff, Hilary R. Weeks, George Wilding, Michael S. Huie, Courtney M. Hallahan, Sarita Dubey
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 4(4)
Introduction Vorinostat is a small molecule inhibitor of histone deacetylase, and has shown preclinical activity in non-small cell lung cancer (NSCLC). Methods Patients with relapsed NSCLC were eligible. Patients received oral vorinostat, 400 mg dail
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae77f4d36dc45559a1ee17fcc92f462d
https://pubmed.ncbi.nlm.nih.gov/19347984
https://pubmed.ncbi.nlm.nih.gov/19347984